FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077885909> ?p ?o ?g. }

• W2077885909 endingPage "406" @default.
• W2077885909 startingPage "400" @default.
• W2077885909 abstract "Arsenic trioxide (As(2)O(3)) was found to induce apoptosis in certain types of cancer cells including acute promyelocytic leukemia, and recently in solid tumors. We have previously demonstrated that As(2)O(3) has a therapeutic effect on cervical cancer by apoptosis promotion in vitro and in vivo. Here we further our study on the role of arsenic trioxide in regulating invasive activity of cervical cancer cells in vitro and in vivo.The effects of As(2)O(3) on human cervical cancer cell lines (HeLa, SiHa, Caski) adhesion, migration and invasion were observed by means of cell adhesion test, cell migration test and cell invasion test. The effects of As(2)O(3) on p-IkappaB, MMP-2, E-cadherin, caveolin-1 and beta-catenin protein expressions of tumor cells were determined by Western blot. In addition, the effects of As(2)O(3) on NF-kappaB activity of tumor cells were analyzed by immunoblot in whole lysates, cytosol and nucleus, respectively. In animal experiments, cervical cancer cells TC-1 were injected into tail veins of C57BL/6 mice and then the mice were treated by intraperitoneal injection of different doses As(2)O(3). Lung weights and the foci on the surface of lungs were measured.As(2)O(3) inhibited attachment of tumor cells to Fibronectin and Matrigel, reduced cell motility and inhibited tumor invasion potential. As(2)O(3) treatment also resulted in a positive regulation of caveolin-1, upregulation of E-cadherin and decreased activity of beta-catenin, NF-kappaB and NF-kappaB-regulated gene MMP-2. In animal experiments, lung weights in PBS group (0.31+/-0.07 g) were significantly elevated compared with those in As(2)O(3)-treated groups (0.21+/-0.03 g and 0.17+/-0.03 g) also As(2)O(3) reduced number of metastatic lesions of lungs (15.4+/-3.5 vs. 8.3+/-2.0 and 6.3+/-2.3) in a dose-dependent manner.This study is the first to report the effectiveness of As(2)O(3) as an inhibitor of cervical cancer invasion both in vitro and in vivo, suggesting a potential clinical application of As(2)O(3) in cervical cancer therapies combining apoptosis induction and metastasis inhibition." @default.
• W2077885909 created "2016-06-24" @default.
• W2077885909 creator A5005260055 @default.
• W2077885909 creator A5009085464 @default.
• W2077885909 creator A5015152606 @default.
• W2077885909 creator A5048141581 @default.
• W2077885909 creator A5064521563 @default.
• W2077885909 creator A5079657615 @default.
• W2077885909 creator A5079920320 @default.
• W2077885909 creator A5084795769 @default.
• W2077885909 date "2007-08-01" @default.
• W2077885909 modified "2023-10-01" @default.
• W2077885909 title "Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo" @default.
• W2077885909 cites W1799444595 @default.
• W2077885909 cites W1963827828 @default.
• W2077885909 cites W1977049975 @default.
• W2077885909 cites W1996267589 @default.
• W2077885909 cites W2028542401 @default.
• W2077885909 cites W2034598992 @default.
• W2077885909 cites W2042470484 @default.
• W2077885909 cites W2050588267 @default.
• W2077885909 cites W2061385217 @default.
• W2077885909 cites W2061656219 @default.
• W2077885909 cites W2063201149 @default.
• W2077885909 cites W2065585650 @default.
• W2077885909 cites W2069814114 @default.
• W2077885909 cites W2079214951 @default.
• W2077885909 cites W2091605975 @default.
• W2077885909 cites W2095440386 @default.
• W2077885909 cites W2106969589 @default.
• W2077885909 cites W2136825258 @default.
• W2077885909 cites W2143646667 @default.
• W2077885909 cites W2147921405 @default.
• W2077885909 cites W2157452165 @default.
• W2077885909 cites W2166781237 @default.
• W2077885909 cites W2329562209 @default.
• W2077885909 cites W2331176038 @default.
• W2077885909 doi "https://doi.org/10.1016/j.ygyno.2007.04.016" @default.
• W2077885909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17512576" @default.
• W2077885909 hasPublicationYear "2007" @default.
• W2077885909 type Work @default.
• W2077885909 sameAs 2077885909 @default.
• W2077885909 citedByCount "65" @default.
• W2077885909 countsByYear W20778859092012 @default.
• W2077885909 countsByYear W20778859092013 @default.
• W2077885909 countsByYear W20778859092014 @default.
• W2077885909 countsByYear W20778859092015 @default.
• W2077885909 countsByYear W20778859092016 @default.
• W2077885909 countsByYear W20778859092017 @default.
• W2077885909 countsByYear W20778859092018 @default.
• W2077885909 countsByYear W20778859092019 @default.
• W2077885909 countsByYear W20778859092020 @default.
• W2077885909 countsByYear W20778859092021 @default.
• W2077885909 countsByYear W20778859092022 @default.
• W2077885909 countsByYear W20778859092023 @default.
• W2077885909 crossrefType "journal-article" @default.
• W2077885909 hasAuthorship W2077885909A5005260055 @default.
• W2077885909 hasAuthorship W2077885909A5009085464 @default.
• W2077885909 hasAuthorship W2077885909A5015152606 @default.
• W2077885909 hasAuthorship W2077885909A5048141581 @default.
• W2077885909 hasAuthorship W2077885909A5064521563 @default.
• W2077885909 hasAuthorship W2077885909A5079657615 @default.
• W2077885909 hasAuthorship W2077885909A5079920320 @default.
• W2077885909 hasAuthorship W2077885909A5084795769 @default.
• W2077885909 hasConcept C121608353 @default.
• W2077885909 hasConcept C126322002 @default.
• W2077885909 hasConcept C142724271 @default.
• W2077885909 hasConcept C150903083 @default.
• W2077885909 hasConcept C190283241 @default.
• W2077885909 hasConcept C202751555 @default.
• W2077885909 hasConcept C207001950 @default.
• W2077885909 hasConcept C2777366897 @default.
• W2077885909 hasConcept C2780386689 @default.
• W2077885909 hasConcept C502942594 @default.
• W2077885909 hasConcept C54355233 @default.
• W2077885909 hasConcept C55493867 @default.
• W2077885909 hasConcept C71924100 @default.
• W2077885909 hasConcept C81885089 @default.
• W2077885909 hasConcept C86803240 @default.
• W2077885909 hasConcept C96232424 @default.
• W2077885909 hasConceptScore W2077885909C121608353 @default.
• W2077885909 hasConceptScore W2077885909C126322002 @default.
• W2077885909 hasConceptScore W2077885909C142724271 @default.
• W2077885909 hasConceptScore W2077885909C150903083 @default.
• W2077885909 hasConceptScore W2077885909C190283241 @default.
• W2077885909 hasConceptScore W2077885909C202751555 @default.
• W2077885909 hasConceptScore W2077885909C207001950 @default.
• W2077885909 hasConceptScore W2077885909C2777366897 @default.
• W2077885909 hasConceptScore W2077885909C2780386689 @default.
• W2077885909 hasConceptScore W2077885909C502942594 @default.
• W2077885909 hasConceptScore W2077885909C54355233 @default.
• W2077885909 hasConceptScore W2077885909C55493867 @default.
• W2077885909 hasConceptScore W2077885909C71924100 @default.
• W2077885909 hasConceptScore W2077885909C81885089 @default.
• W2077885909 hasConceptScore W2077885909C86803240 @default.
• W2077885909 hasConceptScore W2077885909C96232424 @default.
• W2077885909 hasIssue "2" @default.
• W2077885909 hasLocation W20778859091 @default.

• next